Twist Bioscience (TWST) Form 144 Filed for 1,840-Share Sale
Rhea-AI Filing Summary
Form 144 filed for Twist Bioscience Corporation (TWST) reporting an intended sale of common stock. The notice shows 1,840 shares to be sold through Fidelity Brokerage Services with an aggregate market value of $47,774.13 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 via restricted stock vesting and relate to compensation. The issuer has 60,360,925 shares outstanding per the form. Recent disposals by the same person, Patrick Finn, are listed: 1,877 shares (05/21/2025, $55,835.87), 209 shares (07/02/2025, $7,564.36), 2,232 shares (07/23/2025, $79,773.02), and 3,189 shares (08/04/2025, $90,453.11).
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale from restricted stock vesting; amounts are small relative to outstanding shares and appear non-material.
The filing documents a proposed sale of 1,840 common shares by an insider via a broker, acquired the prior day through restricted stock vesting and characterized as compensation. The form also discloses four prior small sales totaling 7,507 shares over the past three months with disclosed gross proceeds. Compared with the reported 60,360,925 shares outstanding, these transactions represent an immaterial ownership shift and are consistent with typical post-vesting selling activity rather than a company-level development.
TL;DR: Disclosure aligns with Rule 144 requirements; signer affirms no undisclosed material information.
The notice includes the required Rule 144 details: acquisition date, nature of acquisition (restricted stock vesting), broker name, and recent sales history for the reporting person, Patrick Finn. The signature/representation language affirms absence of undisclosed material information. There is no indication of a trading plan date on the form, and nothing in this filing signals governance changes or regulatory concerns.